• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Ryan Jane

    4/18/25 8:02:08 AM ET
    $NEUP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NEUP alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Ryan Jane

    (Last) (First) (Middle)
    100 SUMMIT DRIVE

    (Street)
    BURLINGTON MA 01803

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Neuphoria Therapeutics Inc. [ NEUP ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    04/16/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (1) 04/16/2025 A 6,783 (2) (2) Common Stock 6,783 $0 7,013 D
    Explanation of Responses:
    1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.
    2. Subject to the Reporting Person's continuous service to the Company through the day prior to the Company' next annual shareholder meeting (which is expected to be no later than November 30, 2025), the RSUs shall fully vest at 5:01 PM EST on the day prior to the Company's next annual shareholder meeting.
    /s/ Elaine Wangsawidjaja, Attorney-in-Fact for Jane Ryan 04/17/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NEUP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NEUP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NEUP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Lynx1 Capital Management Lp bought $3,283,108 worth of shares (639,110 units at $5.14) (SEC Form 4)

    4 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)

    10/23/25 7:49:54 PM ET
    $NEUP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NEUP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees

    Company Urges Shareholders to Follow ISS' Recommendation and Vote the WHITE Proxy Card BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today announced that Institutional Shareholders Services ("ISS"), a leading independent proxy advisory firm, has issued a report recommending that Neuphoria shareholders vote on the WHITE proxy card FOR BOTH of the Company's director nominees – Peter Miles Davies and David Wilson. As previously disclosed, Lynx1 Capital

    12/8/25 8:00:00 AM ET
    $NEUP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium

    Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote "FOR" BOTH of Neuphoria's Nominees on the WHITE Proxy Card BURLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to dissident stockholder, Lynx1 Master Fund LP's ("Lynx1"), revised indication of interest to acquire the Company. Lynx1 Operating Outside Neuphoria's R

    12/4/25 8:00:00 AM ET
    $NEUP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions

    BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statements to address what Neuphoria strongly believes is a campaign from Lynx1 Master Fund LP ("Lynx1") full of deception and distraction to deflect attention from its own limitations and its handpicked nominees' shortcomings. The Company urges stockholders to trust Neuphoria's commitment to transparency and value creation over what it believes are Lynx1's fabrications and misdire

    12/1/25 8:00:00 AM ET
    $NEUP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NEUP
    SEC Filings

    View All

    SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.

    DEFA14A - Neuphoria Therapeutics Inc. (0001191070) (Filer)

    12/8/25 4:15:01 PM ET
    $NEUP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.

    DEFA14A - Neuphoria Therapeutics Inc. (0001191070) (Filer)

    12/4/25 4:15:49 PM ET
    $NEUP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.

    DEFA14A - Neuphoria Therapeutics Inc. (0001191070) (Filer)

    12/1/25 4:15:32 PM ET
    $NEUP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NEUP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Lynx1 Capital Management Lp bought $3,283,108 worth of shares (639,110 units at $5.14) (SEC Form 4)

    4 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)

    10/23/25 7:49:54 PM ET
    $NEUP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Lynx1 Capital Management Lp claimed ownership of 236,218 shares (SEC Form 3)

    3 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)

    10/23/25 7:47:16 PM ET
    $NEUP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President and CEO Papapetropoulos Spyros

    4 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)

    9/2/25 7:02:44 AM ET
    $NEUP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NEUP
    Financials

    Live finance-specific insights

    View All

    Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process

    BURLINGTON, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced that its Board of Directors (the "Board") has determined to adopt a limited-duration stockholder rights plan (the "Rights Plan"), effective immediately. The Board adopted the Rights Plan in response to significant and rapid accumulations of the Company's publicly traded common stock by certain investors.   The Rights Plan is intended to protect the interests of the Company and its stockholders, help ensure that all interested parties have the oppo

    10/27/25 4:29:10 PM ET
    $NEUP
    Biotechnology: Pharmaceutical Preparations
    Health Care